Articles by Michael B. Glomb

The 340B program continues to garner the attention of Congress and the Trump Administration.  In a recent flurry of activity, the Senate Health, Education, Labor and Pensions (HELP) Committee held its second hearing on the 340B program on May 15.  Unlike the first HELP hearing in early April, which focused…

Three hearings before the House Energy and Commerce (E&C) Committee and its Oversight and Investigation Subcommittee[1] have culminated in an 80-page report (Report) containing the E&C Committee’s findings and review of the federal 340B drug discount program.[2]  The Report does not directly address 340B program contract pharmacies, though the E&C…

The closing months of 2017 saw a flurry of activity related to the 340B drug pricing program, both as a topic of legislative and regulatory actions, and the subject of litigation. The recent developments are focused on hospitals participating in the 340B Program, and do not directly impact federally-qualified health…

On November 1, 2017, the Centers for Medicare & Medicaid Services (CMS) finalized the Hospital Outpatient Prospective Payment System (HOPPS) Final Rule for 2018.  The Final Rule retains a controversial proposal to cut Medicare Part B drug reimbursement for products purchased under the 340B Program and billed through the HOPPS.…

On October 11, 2017, the Oversight and Investigations Subcommittee of the House Energy and Commerce Committee convened a hearing on the use of 340B program savings by covered entities.[1]  The subcommittee solicited testimony from five covered entity representatives, including three representing hospitals, one representing a Ryan White HIV/AIDS Program grantee,…